Association between FAS polymorphism and prostate cancer development

作者：Lima L; Morais A; Lobo F; Calais da Silva F M; Calais da Silva F E; Medeiros R^*

来源：Prostate Cancer and Prostatic Diseases, 2008, 11(1): 94-98.

DOI：10.1038/sj.pcan.4501002

• apoptosis
• polymorphism
• FAS
• CD95
• sFAS

The role of FAS polymorphisms in prostate cancer has not been studied. Using the PCR-based restriction fragment-length polymorphism methodology, we evaluated FAS gene locus -670 genotypes in DNA from 904 men: 657 prostate cancer patients and 247 healthy controls. We found that carriers of AG or GG genotypes have a statistically significant protection ( odds ratio ( OR)=0.30; confidence interval ( CI): 0.20-0.44 and OR 0.22; CI: 0.12-0.74, respectively) for disease with extra-capsular invasion. Taken together, a 72% protection was found for G allele carriers ( OR=0.28; CI: 0.19-0.41). Fas exist as membrane-bound and soluble forms and with opposite roles. They derive from the same gene by alternative splicing. Membrane Fas receptors trigger apoptosis whereas, on the other hand, soluble Fas ( sFas) bind to Fas ligand antagonizing Fas-Fas ligand apoptotic pathway. Our results suggest that G allele may reduce sFas levels preventing the apoptotic inhibition caused by the soluble form.

• 出版日期2008-3